SSSunati Sahoo

Sunati Sahoo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Sunati Sahoo has a total of 84 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Endotrophin Is a Circulating Fibroinflammatory Biomarker Associated with Treatment Response in Human Metastatic ER+ Breast Cancer

    by Bethania Santos, Dawei Bu, Megan Virostek, Ethan Johnson, Cheryl Lewis, Lavanya Vumma, Sunati Sahoo, Yan Peng, Ningyan Zhang, Zhiqiang An, et al.

    Purpose: Soluble factors emanating from fibroinflammatory processes are emerging as cancer biomarkers and therapeutic targets. Endotrophin (ETP), a collagen VI proteolytic fragment, is elevated in human patients with breast cancer and drives tumor progression in rodent breast cancer models, an effect which neutralizing antibodies can abrogate. This implies that tracking or targeting elevated ETP levels could inform breast cancer therapeutic strategies. However, we lack precise knowledge about the impact of ETP in specific breast cancer subtypes and whether circulating levels provide predictive or prognostic information. Experimental Design: To address these gaps, we assessed circulating ETP levels among patients with breast cancer (n = 191 samples from 98 patients) undergoing various treatment modalities, as well as patients with ovarian neoplasia (n = 29) and healthy controls (n = 19). Results: We observed higher circulating ETP levels in estrogen receptor (ER)–positive, HER2-negative (HER2-) tumors compared with triple-negative breast cancer (TNBC) in both early-stage and metastatic settings {median [interquartile range (IQR)], 35.98 (25.31–55.05) vs. 19.67 (9.23–42.07) ng/mL, respectively}. However, circulating ETP levels were associated with treatment response only in the metastatic setting. ETP was readily detected in tumor specimens (n = 54) and adjacent benign sections (n = 28) from various breast tumor types, suggesting that both autocrine and paracrine ETP production may be important drivers of tumor growth. Conclusions: In summary, these findings identify circulating ETP as a potential biomarker in ER+ metastatic breast cancer and support further investigation of its relationship with disease activity and the development of ETP-targeting agents.

  • Intraoperative evaluation of sentinel lymph nodes in patients with breast cancer treated with systemic neoadjuvant therapy: a systematic review and meta-analysis of diagnostic studies

    by Mariela Huerta-Rosario, Carlos Quispe-Vicuña, Dante Julca-Marín, Carlos J Zumaran-Nuñez, Hans Baltazar-Ñahui, Luis M Acuña-Chávez, Fiorella Medina-Navia, Wendy Nieto-Gutierrez, Carlos Alva-Diaz, Sunati Sahoo

    Background Frozen section (FS) and touch imprint (TI) are common intraoperative evaluation (IOE) techniques for sentinel lymph nodes (SLNs) in breast cancer surgery. Their accuracy in patients receiving neoadjuvant systemic therapy (NST) remains variable. Objective To summarise evidence on the diagnostic accuracy of FS and TI in the NST context. Methods A systematic search of PubMed, Embase, Scopus and Web of Science was conducted through April 2024 for studies evaluating FS and/or TI in SLNs of breast cancer patients treated with NST. Meta-analysis was performed using the logit function, and Revised Tool for the Quality Assessment of Diagnostic Accuracy Studies-2 and Grading of Recommendation, Assessment, Development and Evaluation were employed to assess risk of bias and evidence certainty. Results 20 studies were included. At the lymph node level, TI demonstrated pooled sensitivity and specificity of 0.54 and 1.00, respectively, while FS achieved 0.85 and 0.99. At the patient level, TI showed sensitivity and specificity of 0.72 and 1.00, while FS reached 0.82 and 0.98. Combined, FS and TI presented pooled sensitivity and specificity of 0.59 and 1.00 at the patient level. Risk of bias was frequently unclear, and the certainty of evidence for both techniques ranged from low to very low. Conclusion FS exhibits higher sensitivity and specificity than TI at both lymph node and patient levels, but evidence certainty remains limited. Further prospective, blinded studies are needed to validate these findings and optimise IOE methods for NST-treated patients. PROSPERO registration number CRD42023483079.


  • Changes Related to Breast Surgery and Neoadjuvant Therapy

    by Sunati Sahoo, Helena Hwang, Stephen J. Seiler

  • Intraoperative evaluation of sentinel lymph nodes in patients with breast cancer treated with systemic neoadjuvant therapy

    by Mariela Huerta-Rosario, Mariam Mir, Carlos Quispe-Vicuña, Helena Hwang, Venetia Sarode, Yan Peng, Yisheng Fang, Marilyn Leitch, Sunati Sahoo

    Aims Touch preparation (TP) and frozen section (FS) are the two methods routinely used in the intraoperative evaluation (IOE) of sentinel lymph nodes (SLNs) to detect metastases in patients with breast cancer. Both methods are extremely sensitive and specific in the primary surgery (non-neoadjuvant systemic therapy (non-NST)) setting. Since NST introduces unique challenges in the IOE of SLNs, the aim was to determine the accuracy of TP and FS in the IOE of SLNs in the NST setting and compare the results with the non-NST setting and to examine factors that contribute to any differences. Methods We analysed 871 SLNs from 232 patients (615 SLNs from NST and 256 SLNs from non-NST settings) between 2016 through 2019. Results In the NST group, TP alone (n=366) had a sensitivity of 45.7% and specificity of 99.7%; FS alone (n=90) had a sensitivity of 83.3% and specificity of 100%. When both TP and FS (n=135) were used, the sensitivity was 80.3% and the specificity was 98.6%. In the non-NST group, TP alone (n=193) had a sensitivity of 66.7% and specificity of 100%; FS alone (n=22) had a sensitivity and specificity of 100%; and combined TP and FS (n=34) had a sensitivity and specificity of 100% and 96%, respectively. Conclusions Evaluating SLNs intraoperatively in the NST setting can be challenging secondary to therapy-related changes. In the NST setting, FS has higher sensitivity and specificity compared with TP for the IOE of SLNs and should be the preferred method.


  • Open Access

    Standardizing Pathologic Evaluation of Breast Carcinoma After Neoadjuvant Chemotherapy

    by Sunati Sahoo, Gregor Krings, Yunn-Yi Chen, Jodi M. Carter, Beiyun Chen, Hua Guo, Hanina Hibshoosh, Emily Reisenbichler, Fang Fan, Shi Wei, et al.

    Context.—: Neoadjuvant systemic therapy refers to the use of systemic agent(s) for malignancy prior to surgical treatment and has recently emerged as an option for most breast cancer patients eligible for adjuvant systemic therapy. Consequently, treated breast carcinomas have become routine specimens in pathology practices. A standard protocol has not yet been universally adopted for the evaluation and reporting of these specimens. The American Joint Committee on Cancer staging system recognizes the challenges in staging breast carcinomas after neoadjuvant treatment and provides important data points but does not currently provide detailed guidance in estimating the residual tumor burden in the breast and lymph nodes. The Residual Cancer Burden system is the only Web-based system that quantifies treatment response as a continuous variable using residual tumor burden in the breast and the lymph nodes. Objective.—: To provide clarifications and guidance for evaluation and reporting of postneoadjuvant breast specimens, discuss issues with the current staging and reporting systems, and provide specific suggestions for future modifications to the American Joint Committee on Cancer system and the Residual Cancer Burden calculator. Data Sources.—: English-language literature on the subject and the data from the I-SPY 2, a multicenter, adaptive randomization phase 2 neoadjuvant platform trial for early-stage, high-risk breast cancer patients. Conclusions.—: This article highlights challenges in the pathologic evaluation and reporting of treated breast carcinomas and provides recommendations and clarifications for pathologists and clinicians. It also provides specific recommendations for staging and discusses future directions.


  • Lymphangitic spread of invasive lobular carcinoma to the contralateral breast

    by Zachariah Burns, Lena Omar, Lindsay Compton, Jody Hayes, Sunati Sahoo, Kanwal Merchant


  • Open Access

    Combined Targeting of Estrogen Receptor Alpha and XPO1 Prevent Akt Activation, Remodel Metabolic Pathways and Induce Autophagy to Overcome Tamoxifen Resistance

    by Eylem Kulkoyluoglu-Cotul, Brandi Patrice Smith, Kinga Wrobel, Yiru Chen Zhao, Karen Lee Ann Chen, Kadriye Hieronymi, Ozan Berk Imir, Kevin Duong, Caitlin O’callaghan, Aditi Mehta, et al.

    A majority of breast cancer specific deaths in women with ERα (+) tumors occur due to metastases that are resistant to endocrine therapy. There is a critical need for novel therapeutic approaches to resensitize recurrent ERα (+) tumors to endocrine therapies. The objective of this study was to elucidate mechanisms of improved effectiveness of combined targeting of ERα and the nuclear transport protein XPO1 in overcoming endocrine resistance. Selinexor (SEL), an XPO1 antagonist, has been evaluated in multiple late stage clinical trials in patients with relapsed and/or refractory hematological and solid tumor malignancies. Our transcriptomics analysis showed that 4-Hydroxytamoxifen (4-OHT), SEL alone or their combination induced differential Akt signaling- and metabolism-associated gene expression profiles. Western blot analysis in endocrine resistant cell lines and xenograft models validated differential Akt phosphorylation. Using the Seahorse metabolic profiler, we showed that ERα-XPO1 targeting changed the metabolic phenotype of TAM-resistant breast cancer cells from an energetic to a quiescent profile. This finding demonstrated that combined targeting of XPO1 and ERα rewired the metabolic pathways and shut down both glycolytic and mitochondrial pathways that would eventually lead to autophagy. Remodeling metabolic pathways to regenerate new vulnerabilities in endocrine resistant breast tumors is novel, and given the need for better strategies to improve therapy response in relapsed ERα (+) tumors, our findings show great promise for uncovering the role that ERα-XPO1 crosstalk plays in reducing cancer recurrences.


  • Pathologic Findings of Breast Lesions Detected on Magnetic Resonance Imaging

    by Seema B. Jabbar, Beverly Lynch, Stephen Seiler, Helena Hwang, Sunati Sahoo

    Context.—: Breast magnetic resonance imaging (MRI) is now used routinely for high-risk screening and in the evaluation of the extent of disease in newly diagnosed breast cancer patients. Morphologic characteristics and the kinetic pattern largely determine how suspicious a breast lesion is on MRI. Because of its high sensitivity, MRI identifies a large number of suspicious lesions. However, the low to moderate specificity and the additional cost have raised questions regarding its frequent use. Objectives.—: To identify the pathologic entities that frequently present as suspicious enhancing lesions and to identify specific MRI characteristics that may be predictive of malignancy. Design.—: One hundred seventy-seven MRI-guided biopsies from 152 patients were included in the study. The indication for MRI, MRI features, pathologic findings, and patient demographics were recorded. The MRI findings and the pathology slides were reviewed by a dedicated breast radiologist and breast pathologists. Results.—: Seventy-one percent (126 of 177) of MRI-guided breast biopsies were benign, 11% (20 of 177) showed epithelial atypia, and 18% (31 of 177) showed malignancy. The vast majority (84%; 62 of 74) of MRI lesions with persistent kinetics were benign. However, 57% (17 of 30) of lesions with washout kinetics and 65% (62 of 95) of mass lesions were also benign. Conclusions.—: Magnetic resonance imaging detects malignancies undetected by other imaging modalities but also detects a wide variety of benign lesions. Benign and malignant lesions identified by MRI share similar morphologic and kinetic features, necessitating biopsy for histologic confirmation.